Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises funds managed by Triton
Mandate

Vinge advises funds managed by Triton

November 13, 2017 Banking and Finance

Vinge has advised funds managed by Triton in connection with the acquisition of KEWAB, a supplementary acquisition to Akeab. KEWAB is a leading supplier of excavation services, facility and power supply work in western Sweden.

KEWAB and Akeab will be included as sister companies in an infrastructure group, focused on facility and construction work, owned by Triton and the management in the relevant company.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Oscar Rydén, Johanna Wiberg and Michaela Cronemyr. Partner Albert Wållgren and associates Linn Adelwald and André Isacson provided financing advice. Partner Marcus Glader and associates Xandra Ståhlberg and Annika Nyberg Ekenberg provided competition law advice.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024